因理想出发，以方法致胜，凭执行抵达 | Bilingual

2026年，药明康德步入了第26载春秋。

从实验室里一个科学灵感的萌芽，到惠及全球病患的一剂良药，药明康德始终以一体化CRDMO平台为桥，连接科学构想与病患福祉，践行着“让天下没有难做的药，难治的病”的初心，陪伴客户走过从研发到生产的每一步。

赋能客户的持续成功、CRDMO业务模式的独特优势，以及全球团队的卓越执行，正是公司一往无前、持续增长的动力之源。

在2026药明康德年度颁奖盛典上，公司首席财务官施明女士站上颁奖舞台，向每一位获奖者及A+伙伴致以诚挚的祝贺。在她的眼中，支撑公司一路走来的，从来不只是账面上的数字。驱动药明康德持续增长的动力，来自客户的成功，也来自每一位“做对的事，把事做极”的药明康德人。

她将这些年与公司同行的感悟，凝练成一次关于伟大理想、对的方法与极致执行的真诚分享：因理想出发，以方法致胜，凭执行抵达。

以下是施明女士的演讲实录。

因理想出发，以方法致胜，凭执行抵达

——2026年年度盛典A+优秀员工及团队颁奖典礼开场致辞

亲爱的药明康德伙伴们、今晚最闪耀的获奖者们：

大家好！今晚，我们在这里，向每一位获奖者及A+伙伴致敬。你们是全体药明康德人的优秀代表，也让我们看到了大家共同追求的样子。A+，是“找极限、做极致、成极客”中极客的代表，更是我们长期坚守“做对的事，把事做极”所淬炼出的硕果。

A+不只是一个考评等级，更是一种标准——在看起来已经够好的时候，我们还愿意再多走一步。

我的日常工作，离不开报表与数字。真正打动我、让我感到踏实安心的，从来不只是账面上的结果，而是数字背后，支撑我们一路走来的——伟大的理想、对的方法，还有极致的执行。

首先，是伟大的理想。它是最初把我们凝聚在一起的初心。这份理想，始终纯粹与清晰：“让天下没有难做的药，难治的病”。今天，这份理想连接着全球三十多个国家、数千家合作伙伴。从实验室里的一个科学灵感，到真正交到患者手中的一剂良药，这条创新之路漫长且充满未知。而我们所做的，就是陪伴分子的成长，见证科学的落地，做这条远征之路上最坚实、最值得托付的赋能桥梁。

其次，是引领向前的对的方法。二十多年来，公司最宝贵的沉淀，是蹚出了一条独特的路——一体化、端到端的CRDMO模式，一路陪伴客户的分子，从早期研究走向规模化生产。在我们的各个基地里，不同部门的伙伴之间，可能只隔着一条走廊。但对于整个生物医药创新而言，这条走廊连接起的，是少走弯路的极致效率，也是不容偏差的专业与精准。

对的方法，更是对质量底线始终如一的敬畏。依托全球统一的质量体系，在去年一整年，我们迎接了来自全球监管机构、客户和第三方的741次审计与检查，平均下来，每个工作日接近3次。没有一项严重发现。这就是药明康德人对“做对的事，把事做极”最有底气的回答。

第三，是把美好蓝图一步步变成现实的极致执行。理想定方向，方法定路径，而执行，最终决定结果。说到执行，让我想起一句话：“困难的事情可以立刻去做，不可能的事情，只是需要更长一点时间。”我想，这正是我们每一位药明康德人极致执行的真实写照。在行业里，很多人敬畏我们的交付速度。药明康德的快，从来不是盲目冲刺；它是有准备的速度、有组织的速度，更是有质量的速度。

前不久，公司公布了前三季度的经营成绩单：营业收入达到455.4亿元，持续经营业务同比增长46.3%；经调整non-IFRS归母净利润达到183.8亿元，同比增长74.4%；仅仅前三季度，我们的收入和利润就已经全面超过去年全年。

基于赋能客户取得的更大成功，我们更是再次上调了全年的业绩指引：预计今年整体收入将突破610亿元，持续经营业务收入同比增长超过40%。这些数字本身已经很有说服力；放在一个更长的产业周期里去观察，更能看出它们的分量。这几年，行业环境愈加多变，科学创新也愈加复杂，整个行业面对的是同样的挑战和机遇。在这样的背景下，我们的业务规模将达到2018年的约8倍，行业平均约为5倍；2022年以来，行业平均复合增长约11%，我们达到了24%。这也说明：环境越复杂，客户越需要一个值得托付、能带来确定性的赋能平台。规模，从来不是我们的天花板。

这样的增长，并不是某个瞬间的突然爆发，而是漫长坚守后的水到渠成。报表上的每一个数字，都是伙伴们在实验室里、在生产线上，凭着专业与专注，一笔一笔扎实写下来的。全球创新者对药明康德的信任，就是这样在我们一次又一次“说到做到”的交付中，点滴积累，深深沉淀下来的。

把事情做对，把事情做极，创造出来的价值就会像树木一样自然生长，并生生不息地——流向客户，流向病患，流向社会，并最终流向我们身边的每一位员工。

流向客户——我们陪伴客户的分子从最初的萌芽一路走向商业化，成为了全球医药创新不可或缺的坚实依托与“研发基础设施”。

流向病患——每一份严谨的报告、每一批可靠的交付，都在为生命多添一分希望：为每一位患者、每一个家庭，争取一个奇迹。

流向社会——从绿色化学，到乡村孩子们的公益伴读；从社区里的志愿服务，到第一时间的灾害驰援；从道琼斯、富时罗素等国际指数的赞誉，到全球CDP气候与水安全的“双A”评级。“做对的事，把事做极”，不仅是我们赋能创新的底线准则，也是公司作为一家全球企业，对这个世界最朴素的担当与温度。

流向身边的每一位员工！——“诚实敬业，共苦共享”。公司连续四年荣膺“中国杰出雇主”，我们坚信：只有把大家真真切切地放在心上，大家才会把共同的事业稳稳地扛在肩上。公司会持续加大对员工的激励与关怀，用实实在在的回报，不负每一份默默的坚守，鼓励每一位把事做极的伙伴！

山，没有捷径。赋能医药研发就像攀登险峰，真正关乎生命的伟大旅程，极少由戏剧性的飞跃所定义，它靠的，永远是我们在风雨陡坡前，一步一个脚印的稳健前行。

面向未来，让我们继续：怀揣伟大的理想，坚持对的方法，追求极致的执行，把每一份希望送达！

因为我们始终深信：科学，能够改变生命；而你们，就是让改变真正发生的人：A+那一横，是我们共同铸就、寸步不让的标准与专业；而那一竖，正是大家在标准之上，凭着热爱与担当，永远多走出的那一步。

致敬A+，致敬每一位获奖伙伴，致敬每一个在平凡日常中选择多走一步的你！让我们携手并肩，继续“极”往无前！去赋能客户更大的成功！

谢谢大家，祝大家度过一个难忘而美好的夜晚！

WuXi AppTec CFO Ms. Florence Shi: Driven by Great Vision, Succeed by Right Strategy, and Achieve by Excellent Execution

In 2026, WuXi AppTec enters its 26th year. Helping an innovative concept in the lab become a medicine that reaches patients around the world, the company has built its integrated CRDMO (Contract Research, Development and Manufacturing Organization) platform as a bridge between scientific ideas and patient benefit. Guided by its founding vision to realize “every drug can be made, and every disease can be treated”, the company has stood alongside customers at every stage, from research and development to manufacturing.

The sustained success of customers, the unique advantages of the CRDMO business model, and the excellent execution of WuXi AppTec’s global teams have been the driving forces behind the company’s continued momentum and growth.

At the 2026 WuXi AppTec Annual Awards Ceremony, Ms. Florence Shi, Chief Financial Officer, took the stage to congratulate each award winner and every A+ colleague. In her view, what has carried the company this far is never just the numbers on a balance sheet. The real drivers of WuXi AppTec’s growth are its customers' success and the commitment of every WuXi AppTec employee to "doing the right thing, doing it right."

She delivered a candid keynote speech around three pillars: “Driven by Great Vision, Succeed by Right Strategy, and Achieve by Excellent Execution”

Below is the transcript of Ms. Shi’s speech.

Opening Keynote Speech by Ms. Florence Shi at the 2026 Annual A+ Awards Ceremony

Dear colleagues and every award winner: good evening.

Tonight, we are here to pay tribute to each award winner and to every A+ colleague. You are the very best of WuXi AppTec, and you show us what we can all aspire to become.

A+ honors those who push the boundaries, pursue excellence, and do everything first-time right. It is also the embodiment of our long-term commitment to “doing the right thing, doing it right”.

My day-to-day work revolves around financial statements and numbers. But what truly gives me confidence is never just what the numbers show. It is what lies behind them and what has brought us this far: a great vision, the right strategy, and excellent execution.

First, a great vision — the original reason that brought us together. And it has remained as clear and unwavering as ever: "Every drug can be made, and every disease can be treated." Today, this vision connects WuXi AppTec with partners in more than 30 countries and thousands of customers around the world.

From a scientific inspiration in the lab to a medicine finally reaching patients, the path of innovation is long and full of uncertainty. Our role is to support molecules throughout their development, help turn scientific discoveries into reality, and serve as a reliable partner that customers can count on throughout this journey.

Second, the right strategy to move us forward. Over more than two decades, one of the company's most valuable achievements has been building the unique integrated, end-to-end CRDMO model. It enables us to accompany customers' molecules all the way from early research to large-scale manufacturing. At our sites, colleagues from different functions may be separated by no more than a corridor. But for the broader biopharmaceutical industry, that corridor represents something much bigger: greater efficiency, fewer detours, and the professional rigor and precision that leave no room for error. 

The right strategy also means an unwavering commitment to quality. Backed by a globally consistent quality management system, we underwent 741 audits and inspections by regulatory authorities, customers, and third parties around the world last year. That is nearly three times every working day. And there were no critical findings. This is how we demonstrate, with confidence, what it means to be "doing the right thing, doing it right."

Third, excellent execution that turns a vision into reality. The vision sets our direction, the right strategy shows us the way, but ultimately, execution determines the results. When we talk about execution, I’m reminded of a saying: “Difficult things can be done right away; impossible things just take a little longer.” This captures how WuXi AppTec people approach execution. Across the industry, many peers respect our delivery speed. But WuXi AppTec’s speed has never been about blind sprinting. It is speed built on preparation, strong organization, and, above all, quality.

Not long ago, the company announced its financial results for the first three quarters of the year. Revenue reached RMB 45.54 billion, with revenue from continuing operations up 46.3% year over year. Adjusted non-IFRS net profit reached RMB 18.38 billion, an increase of 74.4%. In just three quarters, both our revenue and profit had already surpassed their full-year totals for last year. 

Driven by the greater success of our customers, we raised our full-year guidance once again. We now expect total revenue to exceed RMB 61 billion this year, with revenue from continuing operations growing by more than 40%. These figures speak for themselves. But their significance becomes even clearer when viewed over a longer industry cycle.

In recent years, the industry has faced an increasingly dynamic environment, while scientific innovation has become more complex. The challenges and opportunities are shared across the sector. Against this backdrop, our business is expected to reach approximately eight times its 2018 scale, compared with around five times for the industry average. Since 2022, the industry's average compound annual growth rate has been approximately 11%, while ours has reached 24%. This suggests that the more complex the environment become, the more customers need a trusted partner that can provide reliability and certainty. Our scale is not our ceiling.

The growth did not happen overnight. It is the natural outcome of years of commitment and hard work. Behind every number in our financial reports are the contributions of colleagues in labs and on manufacturing lines, who have built our results through professionalism, dedication, and attention to detail.

The trust that innovators around the world place in WuXi AppTec has been earned one delivery at a time. When we do the right things and do it right, the value we create grows like a tree, and continues to reach our customers, patients, society, and ultimately, every employee.

To our customers. We support their molecules from earliest stages all the way to commercialization, serving as an indispensable partner and a vital foundation for pharmaceutical innovation worldwide - a true R&D infrastructure for the industry.

To our patients. Every rigorous report and every reliable delivery help bring new hope to patients. Every detail of our work can make a difference, helping patients and their families hold on to the possibility of a better tomorrow - and, sometimes, a miracle.

To the society. Our contributions take many forms: from green chemistry initiatives to reading programs for children in rural communities; from volunteering in local communities to providing immediate assistance in times of disaster. They are also reflected in the recognition we have received, from our inclusion in international indices such as the Dow Jones and FTSE Russell indices to both A ratings in CDP's global climate change and water security rating.

"Doing the Right Thing, Doing It Right" is more than a guiding principle for enabling innovation. It is also how we, as a global company, fulfill our responsibility to the world - with genuine care and a sense of purpose.

And finally, to our employees, every colleague around us. "Integrity and Dedication, Working Together and Sharing Success." For four consecutive years, WuXi AppTec has been recognized as a Top Employer in China. We firmly believe that when people know they are genuinely valued and cared for, they will take shared responsibility for the success of our business. We will continue to invest in employee incentives and well-being, delivering tangible rewards that recognize every employee’s dedication and encourage every colleague to do better.

There are no shortcuts to reaching the summit. Enabling pharmaceutical R&D is much like mountain climbing. Great journeys that touch lives are rarely defined by dramatic leaps forward. They are built step by step, through steady progress even when the path ahead is steep and the weather is against us.

Looking ahead, let us continue to pursue our great vision, stay true to the right strategy, and strive for excellent execution. Together, let us turn every hope into reality!

At WuXi AppTec, we firmly believe that science can change lives. And you are the people who make that change happen. A+ is our promise to hold the line on standards and professionalism and to go one step further, driven by passion and responsibility. Tonight, we salute our A+ honorees. We salute every award-winning colleague and team. And we salute everyone who chooses to go one step further in their everyday work.

Let us stand together and keep pushing the boundary, striving for excellence, and moving forward without hesitation to enable even greater success for our customers!

Thank you, and I wish you all a wonderful and unforgettable evening!

版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。